- Home
- TBBB vs RNA Comparison
TBBB vs RNA Comparison
Compare TBBB & RNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TBBB
- RNA
- Stock Information
- Founded
- TBBB 2004
- RNA 2012
- Country
- TBBB Mexico
- RNA United States
- Employees
- TBBB N/A
- RNA N/A
- Industry
- TBBB
- RNA Biotechnology: Pharmaceutical Preparations
- Sector
- TBBB
- RNA Health Care
- Exchange
- TBBB NYSE
- RNA Nasdaq
- Market Cap
- TBBB 3.3B
- RNA 3.7B
- IPO Year
- TBBB 2024
- RNA 2020
- Fundamental
- Price
- TBBB $28.03
- RNA $31.12
- Analyst Decision
- TBBB Buy
- RNA Strong Buy
- Analyst Count
- TBBB 7
- RNA 10
- Target Price
- TBBB $29.86
- RNA $65.80
- AVG Volume (30 Days)
- TBBB 1.6M
- RNA 1.3M
- Earning Date
- TBBB 03-04-2025
- RNA 03-07-2025
- Dividend Yield
- TBBB N/A
- RNA N/A
- EPS Growth
- TBBB N/A
- RNA N/A
- EPS
- TBBB 0.12
- RNA N/A
- Revenue
- TBBB $2,727,305,465.00
- RNA $10,117,000.00
- Revenue This Year
- TBBB $32.56
- RNA N/A
- Revenue Next Year
- TBBB $29.46
- RNA N/A
- P/E Ratio
- TBBB $235.96
- RNA N/A
- Revenue Growth
- TBBB 29.70
- RNA N/A
- 52 Week Low
- TBBB $19.31
- RNA $13.73
- 52 Week High
- TBBB $35.22
- RNA $56.00
- Technical
- Relative Strength Index (RSI)
- TBBB N/A
- RNA 44.06
- Support Level
- TBBB N/A
- RNA $31.14
- Resistance Level
- TBBB N/A
- RNA $33.37
- Average True Range (ATR)
- TBBB 0.00
- RNA 1.67
- MACD
- TBBB 0.00
- RNA -0.16
- Stochastic Oscillator
- TBBB 0.00
- RNA 11.27
About TBBB BBB FOODS INC
BBB Foods Inc is a company offering grocery hard discount model in Mexico. Also that operates through three subsidiaries namely Tiendas Tres B , Tiendas BBB and Desarrolladora Tres BSA de CV of which the main activity of Tiendas Tres B is the sale, purchase, distribution and marketing of all types of products, items and goods, as well as the establishment, and operation of individual stores and distribution centers for the sale of such products.
About RNA Avidity Biosciences Inc.
Avidity Biosciences Inc is a biotechnology company. The company develops novel Antibody Oligonucleotide Conjugates therapies designed to overcome the current limitations of oligonucleotide therapies in order to treat a wide range of serious diseases. Its product, AOC 1001, is designed to treat a rare monogenic muscle disease.